The biopharma industry is excited about anti-obesity drugs, neurology, and AI, but high rates and patent expirations have dampened investor enthusiasm. Where are the biggest opportunities now? Goldman Sachs Research’s Asad Haider, Chris Shibutani, and Salveen Richter discuss on the sidelines of our 45th Annual Global Healthcare Conference.
Our weekly newsletter with insights and intelligence from across the firm
By submitting this information, you agree to receive marketing emails from Goldman Sachs and accept our privacy policy. You can opt-out at any time.